Kazia Therapeutics Limited (KZIA:NASDAQ) closed at $7.40 on October 15, 2026, up 8.98% on the day. The stock trades 57.5% below its 52-week high of $17.40 and 52.3% above its 52-week low of $4.86. Over the past year, it gained 5.9%. Kazia Therapeutics Limited is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -16.00% | -27.45% | -45.39% | -29.46% | +5.87% |
In 252 trading sessions since October 15, 2025, KZIA closed higher on 120 days (48%). Its best day was November 25, 2025 (+51.36%) and its worst was January 2, 2026 (-27.43%). The stock moved 10% or more in a single session 29 times. It opened at least 5% above the previous day's high 2 times.
Novogen Limited engages in the pharmaceutical research and development business in Australia. The company primarily has two drug technology platforms, which include superbenzopyran (SBPs) and anti-tropomyosin (ATMs). Its SBP technology platform offers Cantrixil, an intra-cavity anti-cancer agent for the treatment of ovarian cancer, malignant ascites, and malignant pleural effusion; and Trilexium for the treatment of brain cancers, neuroblastoma, and melanoma. Its ATM technology platform provides Anisina that destructs cancer cells cytoskeleton. The company is also developing various programs in the areas of regenerative medicine, facioscapulohumeral muscular dystrophy, and lysosomal storage disorder. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.
Find more stocks like KZIA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.